Vivatides Therapeutics Raises $54 Million Series A to Advance Extrahepatic RNA Therapeutics Platform
核心洞察
Vivatides Therapeutics (搜索) successfully closed an oversubscribed $54 million Series A financing round co-led by Qiming Venture Partners (搜索) to advance its extrahepatic RNA delivery platform.
The company has developed a differentiated platform spanning both siRNA and antisense oligonucleotides with advances in ligand conjugation, delivery efficiency, and tissue targeting specificity.
RNA therapeutics are expanding beyond liver-targeted applications into chronic disease areas such as hyperlipidemia (搜索), hypertension (搜索), and oncology (搜索), unlocking substantial market potential.
Vivatides Therapeutics (搜索), a global biotechnology company focused on developing extrahepatic RNA-targeting therapeutics, announced the successful closing of an oversubscribed $54 million Series A financing. The round was co-led by Qiming Venture Partners (搜索) and a leading industry fund, with participation from Highlight Capital (搜索) and TF Capital (搜索), while existing investor Apricot Capital (搜索) continued its support with additional investment.
The financing represents a significant milestone for the company, which has completed both its seed and Series A financings within less than one year of founding in 2025. This rapid fundraising success underscores strong investor confidence in Vivatides' technological innovation and execution capabilities in extrahepatic RNA delivery.
Addressing Critical Delivery Challenges
RNA therapeutics, with their broad target space, high specificity, and durable efficacy, are positioned to become the third major therapeutic modality following small molecules and antibodies. However, traditional RNA therapeutics have largely been limited to liver-targeted applications due to delivery challenges, leaving diseases involving extrahepatic tissues significantly underserved.
"Extrahepatic delivery is the key that will unlock RNA therapeutics from niche rare diseases to broad chronic indications," said Keming Zhou, Founder of Vivatides Therapeutics (搜索). "We believe that overcoming delivery barriers will enable RNA therapeutics to transform treatment paradigms across a wide range of diseases."
With advances in extrahepatic delivery technologies, RNA therapeutics are rapidly expanding beyond rare diseases into large, chronic disease areas such as hyperlipidemia (搜索), hypertension (搜索), and oncology (搜索), unlocking substantial market potential.
Platform Technology and Capabilities
Vivatides has built a differentiated extrahepatic delivery platform with capabilities spanning both siRNA and antisense oligonucleotides (ASO). The company has achieved key advances in ligand conjugation, delivery efficiency, tissue targeting specificity, and safety, with encouraging in vivo results already demonstrated.
The company's globally experienced leadership team includes experts from leading RNA therapeutics companies who have previously led or played key roles in multiple extrahepatic RNA programs, several of which have progressed into clinical development. Combined with strong capabilities in sequence design and target discovery, the platform enables rapid parallel advancement and expansion of a diversified pipeline.
Investor Confidence and Strategic Vision
Dr. Kan Chen, Partner at Qiming Venture Partners (搜索), commented: "We have long been optimistic about the application potential of small nucleic acid drugs across a broader range of disease areas. Continuous advances in extrahepatic targeting technologies are steadily expanding their clinical frontiers. Vivatides Therapeutics (搜索) has demonstrated solid technological expertise and efficient execution capabilities in this field, with encouraging progress achieved on its platform."
Dr. Wei Ding, Partner at Apricot Capital (搜索), noted: "Since its founding, Dr. Zhou and his team have consistently exceeded expectations with exceptional execution in platform development and pipeline advancement. We look forward to Vivatides translating its differentiated platform into breakthrough therapies that benefit patients worldwide and leading the next wave of extrahepatic RNA therapeutics."
Development Plans and Future Outlook
Proceeds from the financing will be used to further advance Vivatides' extrahepatic delivery platform, accelerate multiple pipeline programs into clinical development, and expand its global team and R&D network. Following the financing, the company will further accelerate preclinical optimization and IND-enabling studies, expand its R&D and management teams, and continue to strengthen its extrahepatic delivery platform.
Looking ahead, Vivatides will remain focused on addressing unmet medical needs in high-prevalence extrahepatic diseases, with the goal of becoming a leader in RNA therapeutics and delivering more effective and safer treatment options to patients worldwide.